
Collaboration - September 8, 2021
Positive results from Scandion Oncology and Alligator Bioscience
Alligator Bioscience and Scandion Oncology have announced the conclusion of their collaboration with a very positive outcome. The purpose of the collaboration was to explore the anti-tumor efficacy of the CD40 antibody mitazalimab in chemotherapy-resistant preclinical tumor models as an addition to chemotherapy (FOLFIRINOX) combined with SCO-101. The hypothesis that was tested was to see […]

Financing - March 3, 2020
Scandion Oncology receives DKK 5 million
Scandion Oncology A/S has obtained DKK 5 million from Innovation Fund Denmark for the clinical development of SCO-101 in metastatic pancreatic cancer. The grant of DKK 5 million from Innovation Fund Denmark is earmarked for the clinical phase II development of SCO-101 in metastatic pancreatic cancer. “We are very pleased to receive this soft money […]